Compare GGN & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGN | MGTX |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.2M | 881.7M |
| IPO Year | 2005 | 2018 |
| Metric | GGN | MGTX |
|---|---|---|
| Price | $5.06 | $9.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 429.7K | ★ 607.2K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 10.26% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $314.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.97 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $4.69 | $6.62 |
| 52 Week High | $5.88 | $15.35 |
| Indicator | GGN | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 43.56 |
| Support Level | $5.01 | $8.80 |
| Resistance Level | $5.13 | $10.08 |
| Average True Range (ATR) | 0.08 | 0.53 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 23.75 | 49.03 |
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest the majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.